Literature DB >> 2327383

Overt gastrointestinal bleeding in the course of chronic low-dose aspirin administration for secondary prevention of arterial occlusive disease.

J E Naschitz1, D Yeshurun, M Odeh, H Bassan, I Rosner, E Stermer, N Levy.   

Abstract

We describe 13 patients who developed erosive gastritis with overt gastrointestinal bleeding while receiving 75-250 mg nonbuffered aspirin per day for the secondary prevention of cardiac or cerebrovascular events. The bleeding occurred despite good initial tolerance to aspirin for several months or years. All patients were elderly and had severe atherosclerotic cardiovascular disease. Our data suggest that, contrary to common belief, very low doses of nonbuffered aspirin are attendant with clinically apparent gastrointestinal complications.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2327383

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  6 in total

Review 1.  NSAIDs. Safety implications of over-the-counter availability.

Authors:  S Meckstroth; M Schwartz; N Agrawal
Journal:  Drug Saf       Date:  1992 Jul-Aug       Impact factor: 5.606

2.  Laparoscopic vagotomy: an operation for the 1990s?

Authors:  T V Taylor; D S Bhandarkar
Journal:  Ann R Coll Surg Engl       Date:  1993-11       Impact factor: 1.891

Review 3.  Gastroprotection and nonsteroidal anti-inflammatory drugs (NSAIDS). Rationale and clinical implications.

Authors:  J Hayllar; A Macpherson; I Bjarnason
Journal:  Drug Saf       Date:  1992 Mar-Apr       Impact factor: 5.606

Review 4.  Aspirin for the prevention of cardiovascular events in the elderly.

Authors:  Isabelle Mahé; Alain Leizorovicz; Charles Caulin; Jean-François Bergmann
Journal:  Drugs Aging       Date:  2003       Impact factor: 3.923

5.  Low-dose acetylsalicylic acid use and hemoglobin levels. Effects in a primary care population.

Authors:  A Leibovici; N Lavi; S Wainstok; J Herman; V W Greene
Journal:  Can Fam Physician       Date:  1995-01       Impact factor: 3.275

Review 6.  Nonsteroidal antiinflammatory agents in chemoprevention of colorectal cancer. At what cost?

Authors:  M A Trujillo; H S Garewal; R E Sampliner
Journal:  Dig Dis Sci       Date:  1994-10       Impact factor: 3.199

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.